Sir Jonathan Symonds, CBE

Chairman, GlaxoSmithKline plc

Sir Jonathan R. Symonds, CBE, has served as a member of the Rubius Therapeutics Board of Directors since March 2018. He has extensive international financial and governance experience. He currently serves as Chairman of the Board of Directors for GlaxoSmithKline plc, a global healthcare company and as Chairman for Proteus Digital Health Inc., a digital medicine company. Mr. Symonds is also a Non-Executive Director of Genomics England Limited having previously served as Chairman.

Prior to his current roles, Mr. Symonds was previously Deputy Group Chairman and Senior Independent Director of HSBC Holdings plc, a large international banking and financial institution between 2014 and 2020. Mr. Symonds also served as Chairman of HSBC Bank plc, HSBC’s European subsidiary, which offers services to clients in the UK and Continental Europe. Mr. Symonds was Chief Financial Officer of Novartis AG from 2009 to 2013. Before joining Novartis, he was Partner and Managing Director of Goldman Sachs; Chief Financial Officer of AstraZeneca plc; and Partner at KPMG. His governance experience also includes roles as Non-Executive Director and Chair of the Audit Committees of Diageo plc and QinetiQ Group plc.

Mr. Symonds received a B.A. in business finance and an honorary doctorate in law from the University of Hertfordshire.